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BRIEF
COMMUNICATIONS
-Difluoromethylornithine and
Polyamine Levels in the
Human Prostate: Results of a
Phase IIa Trial
Anne R. Simoneau, Eugene W.
Gerner, Mai Phung, Christine E.
McLaren, Frank L. Meyskens, Jr.
Prostate cancer is the most com-
monly diagnosed malignancy in men
and the second leading cause of male
cancer deaths in the United States (1).
As such, the prevention of prostate can-
cer is of national medical concern. One
approach to prevention of prostate can-
cer is to suppress the polyamine levels in
the prostate, an avenue suggested by
studies indicating that ornithine decar-
boxylase (ODC), the first enzyme in the
polyamine pathway, is overexpressed in
human prostate cancer tissue (2) and is
the target enzyme for -difluorometh-
ylornithine (DFMO). This inhibitor sup-
presses tissue contents of polyamines,
which are required for optimal cell pro-
liferation and differentiation.
Elevated levels of polyamine are as-
sociated with several malignant or pre-
malignant lesions (3–5). Prostate cancer
seems a logical organ system for DFMO
chemoprevention, since ODC activity
and polyamine content are higher in
prostatic tissue than in other mammalian
tissues (6). Also, investigators (7–10)
have demonstrated marked polyamine
suppression by DFMO in rodent pros-
tates and prostate cell lines. Mohan et al.
(2) measured ODC activity in benign
and malignant tissues from the same pa-
tient and found the cancerous portion to
have levels almost three times those of
benign tissue. In addition, they evalu-
ated the ODC activity of prostatic fluid
obtained by massage and found that, in
men with prostate cancer, levels were
50% higher than in men with benign hy-
pertrophy. However, prior to proceeding
with a DFMO prostate cancer chemo-
prevention trial, documentation of the
effects of DFMO on human prostate in
vivo was needed. Because that informa-
tion was unpublished, this phase IIa trial
was implemented. Subsequently, Mess-
ing et al. (11) published the results of a
small placebo-controlled trial of DFMO
on human prostate polyamine levels.
Their study demonstrated reduced levels
of putrescine only. Our study differs
from the study by Messing et al. in that
in our study the reduction of putrescine
was greater, and there was also a statis-
tically significant reduction in the levels
of the polyamines spermidine and
spermine.
The protocol for our study was ap-
proved by the investigational review
board of the University of California,
Irvine, and by the Long Beach Veterans
Administration Medical Center, and
subjects gave written informed consent.
Men who were having a transrectal pros-
tate needle biopsy underwent four addi-
tional core needle biopsies; the speci-
mens obtained at these biopsies were
frozen immediately. If the patient elected
to undergo an invasive prostate proce-
dure, he was asked to continue partici-
pation and to take oral DFMO at a dose
of 0.5 g/m2 once daily for 28 days be-
fore the second procedure. The dosage
chosen was based on prior studies
(12,13), in which patients with colon
polyps were treated with a range of
DFMO doses and polyamine contents in
rectal mucosal biopsy specimens were
assessed. This dose produced polyamine
suppression without side effects (12,13).
Just before the surgical procedure, four
transrectal core biopsy specimens were
taken, frozen, and used for the poly-
amine analysis.
Polyamine analysis was performed
with the use of standard reverse-phase,
ion-paired high-performance liquid
chromatography methods, described
previously (12–14). Polyamine levels
are reported in nanomoles per milligram
protein. The limit of detection of our
method is 0.01 nmol/mg protein. Non-
detectable levels correspond to less than
0.01 nmol/mg. For statistical analysis,
0.01 nmol/mg was imputed when poly-
amine levels were below the limit of de-
tection. All P values were two-sided and
were considered to be statistically sig-
nificant at P<.05. We compared pre-
DFMO and post-DFMO polyamine val-
ues using the Wilcoxon matched-pairs
signed rank test. Prostate-specific anti-
gen values and histologic descriptions of
the prostate are provided in Table 1.
Fig. 1 compares the absolute values
of putrescine, spermidine, spermine, and
the spermidine/spermine ratio before
and after DFMO treatment. Pretherapy
putrescine was detectable before DFMO
administration in six men and was non-
detectable in three men. The average pu-
trescine level was 0.42 nmol/mg (me-
dian, 0.22 nmol/mg; interquartile range,
0.01–0.78 nmol/mg). All men had unde-
tectable levels of putrescine after
DFMO treatment. For the six men with
pre-DFMO putrescine levels of 0.01
nmol/mg or higher, the average percent
decrease from baseline was at least
97.6% (median, 95.0%; P  .031).
Spermidine was measurable in all speci-
mens before DFMO administration. The
average pretreatment level of spermi-
dine was 1.21 nmol/mg (median, 0.81
nmol/mg; interquartile range, 0.51–1.47
nmol/mg). The average level of spermi-
dine after therapy was 0.32 nmol/mg
(median, 0.21 nmol/mg; interquartile
range, 0.08–0.43 nmol/mg); in two
specimens, the levels were undetectable.
The average percent decrease from
baseline was 73.6% (median, 69.0%;
P  .004). The average spermine level
before DFMO administration was 29.14
nmol/mg (median, 28.85 nmol/mg; in-
terquartile range, 13.33–47.39 nmol/
mg); after DFMO administration, it de-
creased in all specimens to an average
level of 14.33 nmol/mg (median, 12.90
nmol/mg; interquartile range, 7.40–22.01
nmol/mg). The average percent decrease
from baseline was 50.8% (median,
55.0%; P  .004). The spermidine/
spermine ratio was calculated for each
specimen. Eight of nine patients had a
decrease in this ratio after DFMO was
given. The average decrease from base-
line was 50% (median, 52%; P  .019).
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In this short-term trial, we were able
to demonstrate a statistically significant
reduction in the levels of prostate poly-
amines after administration of oral DFMO
at a dose of 0.5 g/m2 daily for 28 days.
In 1999, Messing et al. (11) published
results of 2 weeks of oral administration
of DFMO on human prostate polyamine
levels. Men in that study were randomly
assigned to receive either DFMO at a
dose of 0.5 g/m2 for 2 weeks (n  15)
or placebo (n  10) prior to prostatec-
Table 1. Patient demographics*
Patient No.
1 2 3 4 5 6 7 8 9
Routine PSA† 5.8 9.8 2.3 1.7 5.1 2.6 6.3 47.2‡ 4.1
Pre-study PSA† 4.4 Not done 2.3 1.5 16.6§ 11.1§ 8.7 23.2 6.8§
Post-DFMO PSA† 3.7 7.5 2.5 1.4 5 2.3 6.8 35.5 8.2§
Initial pathology
diagnosis ,¶
Atypia Gleason
grade 5
Atypia,
inflammation
Atypia Atypia,
inflammation
Gleason
grade 6
Atypia,
inflammation
Gleason
grade 7
Gleason
grade 6
Procedure Biopsy RRP Biopsy Biopsy TURP RRP Biopsy RRP RRP
Final pathology
diagnosis ,¶
Atypia T3a,
Gleason
grade 6
Gleason
grade 6
BPH BPH,
inflammation
T2b,
Gleason
grade 6
Inflammation T4,
Gleason
grade 8
T2a,
Gleason
grade 6
Days of DFMO 28 28 35 30 30 28 25 29 21
*PSA  prostate-specific antigen; DFMO  -difluoromethylornithine; RRP  radical retropubic prostatectomy; TURP  transurethral resection of
prostate; BPH  benign prostatic hyperplasia.
†Three PSA values are given: 1) routine PSA—drawn prior to study participation as part of routine standard of care; 2) pre-study PSA—drawn the day of
beginning the trial and starting DFMO; and 3) post-DFMO PSA—drawn the day of the second procedure after a month of DFMO.
‡PSA was drawn when patient presented to the emergency room with acute urinary retention. Such retention can elevate the PSA level.
§PSA was drawn within 6 weeks of biopsy; therefore, it may be falsely elevated.
Prostate cancer staging as per the TNM (tumor–node–metastasis) updated 1997 staging system (18) (American Joint Committee on Cancer 1997); histology
as per Gleason Grading System (19). Atypia—findings are suspicious for cancer but the cytologic and/or architectural features are insufficient for a definitive
diagnosis.
¶Initial pathology diagnosis  routine pathology report from the sextant prostate cores. Final pathology diagnosis  routine pathology report from the second
prostate procedure, following DFMO.
Procedures performed after participation in the trial included biopsy (repeat sextant biopsy for abnormal previous biopsy), RRP, and TURP.
Fig. 1. Absolute values for polyamine content in prostatic tissue obtained by core biopsy before and after 28 days of -difluoromethylornithine (DFMO)
treatment. A) Putrescine. B) Spermidine. C) Spermine. D) Spermidine/spermine ratio.
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tomy. The mean putrescine levels were
statistically lower in the DFMO-treated
group (1.43 nmol/mg DNA versus 1.95
nmol/mg DNA; P  .03). There were
no differences in ODC activity or in lev-
els of spermidine or spermine measured
in their study.
A brief review of the two trial de-
signs points to study differences that can
account for the discordant results be-
tween the two studies. Our study had the
advantage that we elected to use each
male as his own control for polyamine
suppression by using samples from the
same male before and after DFMO. Our
data show a wide variation in polyamine
levels among the subjects prior to ma-
nipulation. This variability makes it dif-
ficult to assess differences in a small
control versus treatment group and may
be the reason why only putrescine, with
the smallest variability, was statistically
significantly changed in the trial con-
ducted by Messing et al. (11). A similar
difficulty with the variability in poly-
amine levels was addressed by Mitchell
et al. (15), who reported on polyamine
levels in cervical cancer compared with
levels in normal cervical tissue. These
authors concluded that, because of the
variability in the polyamine levels, large
numbers of subjects would be needed to
see a statistically significant result.
There are also processing issues re-
lated to the manner in which the tissues
were managed between these two stud-
ies. We took cores prior to surgery,
whereas Messing et al. (11) took cores
after the prostate was removed. The im-
pact of ischemia for 1–2 hours on the
prostate is unknown as the prostate is
systematically devascularized and re-
moved. This confounder, therefore, was
not an issue in our study. Another dif-
ference between the studies was the
length of treatment. Our subjects re-
ceived 4 weeks of DFMO, as opposed to
2 weeks in the study by Messing et al.
Administration of oral DFMO for 4
weeks reduces the levels of putrescine,
spermidine, and spermine in a statisti-
cally significant manner in human pros-
tate tissue. The relationship between
overexpression of ODC, elevated levels
of polyamines, and cancer risk has been
explored [reviewed in (16)], and current
chemoprevention trials with DFMO are
ongoing in breast, cervix, colon, and
skin (17). With the information from
this trial, we plan to proceed with a pros-
tate cancer chemoprevention trial with
DFMO.
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NOTES
Editor’s note: F. L. Meyskens, Jr., A. R. Simo-
neau, and E. W. Gerner conduct research spon-
sored by Ilex, the manufacturer of -difluoro-
methylornithine (DFMO). Ilex also supplies
DFMO gratis for the authors’ clinical trials.
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